OncoMatch/Clinical Trials/NCT04742634
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Is NCT04742634 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including DEC-C and MyeloSeq-HD for myelodysplastic syndromes.
Treatment: DEC-C · MyeloSeq-HD — The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic hematopoietic cell transplant
who have received an allogeneic hematopoietic cell transplant
Cannot have received: investigational agent
Not currently receiving any investigational agents
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L and platelets ≥ 50 X 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min using Cockcroft-Gault Formula
Liver function
Total bilirubin ≤ 1.5 x IULN (unless due to hemolysis or Gilbert's disease, per PI discretion); AST(SGOT)/ALT(SGPT) ≤ 3.0 IULN
Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L and platelets ≥ 50 X 10^9/L. Total bilirubin ≤ 1.5 x IULN. AST(SGOT)/ALT(SGPT) ≤ 3.0 IULN. Creatinine clearance ≥ 30 mL/min using Cockcroft-Gault Formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify